---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-026160"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T17:43:58.952440+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q2 revenue up 32% to $20.2M; raises FY 2023 guidance to $75-77M

## Summary
- Revenue $20.2M, up 32% YoY (14% organic, 18% from Coflex/CoFix acquisition).
- Gross margin 61.6%, up from 54.8% in Q2 2022, driven by Coflex/CoFix contribution.
- Net loss $2.2M ($0.02/share) vs $1.7M ($0.02) prior; adjusted EBITDA turned positive at $0.1M.
- Raises FY 2023 revenue guidance to $75-77M from $73-75M, representing 29-33% annual growth.
- CEO Sean Browne highlighted strength across channels and positive adjusted EBITDA ahead of expectations.

## SEC filing metadata
- accession: 0001493152-23-026160
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-026160
- JSON: https://secwatch.observer/filing/0001493152-23-026160.json
- Plain text: https://secwatch.observer/filing/0001493152-23-026160.txt

## Key facts
- Earnings Releases
  Xtant Medical Holdings, Inc. reported second quarter ended June 30, 2023 results: net income -$2.2 million, EPS -$0.02.
  - Period: second quarter ended June 30, 2023
  - Net income: -$2.2 million
  - EPS: -$0.02
  - Result: reported results
  source text: Second quarter 2023 revenue grew 32%, representing organic growth of 14% plus an 18% increase from products added in the acquisition of the Coflex and CoFix lines, to $20.2 million, compared to $15.3 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm
- Earnings Releases
  Xtant Medical Holdings, Inc. reported second quarter ended June 30, 2023 results: net income -$2.2 million, EPS -$0.02.
  - Period: second quarter ended June 30, 2023
  - Net income: -$2.2 million
  - EPS: -$0.02
  - Result: reported results
  source text: Second quarter 2023 net loss totaled $2.2 million, or $0.02 per share, compared to the second quarter 2022 net loss of $1.7 million, or $0.02 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm
- Earnings Releases
  Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $75 million to $77 million. Guidance raised.
  - Period: full year 2023
  - Revenue: $75 million to $77 million
  - Guidance: raised
  - Result: guidance update
  source text: Xtant Medical raises its expectation for full year 2023 revenue to $75 million to $77 million, up from the Company's prior guidance of $73 million to $75 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315223026160/0001493152-23-026160-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.